Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-151 Combinations in Advanced Cancer
NCT02538627Phase 1Terminated
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MM-151 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (HNSCC) (5 arms), sponsored by Merrimack Pharmaceuticals. Primary endpoint: Maximum Tolerated Dose at 1.5 years. Started Aug 2015; status: terminated.
02
Drugs
MM-151
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02538627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538627.